Here are the Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Empagliflozin in nondiabetic individuals with exceptionalities, empagliflozin in nondiabetic individuals synonym, empagliflozin in nondiabetic gastroparesis, empagliflozin in nondiabetic individuals with calcium and magnesium, empagliflozin in nondiabetic ketoacidosis, empagliflozin indonesia, empagliflozin in nondiabetic individuals with calcium and potassium, empagliflozin in nondiabetic individuals undergoing.
Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial
Efficacy of sodium-glucose cotransporter 2 inhibitors for kidney stone prevention in nondiabetic patients is unknown. In a double-blind, placebo-controlled, single-center, crossover phase 2 trial, 53 adults (≥18 and <75 years) with calcium (n = 28) or uric acid (UA; n = 25) kidney stones (at least one previous kidney stone event) without diabetes (HbA1c < 6.5%, no diabetes treatment) were randomized to once daily empagliflozin 25 mg followed by placebo or reverse (2 weeks per treatment). Randomization and analysis were performed separately for both stone types. Primary analyses were conducted in the per protocol set. Primary outcomes were urine relative supersaturation ratios (RSRs) for calcium oxalate (CaOx), calcium phosphate (CaP) and UA—validated surrogates for stone recurrence. Prespecified RSR reductions (≥15%) were met in both groups of stone formers. In patients with calcium stones, empagliflozin reduced RSR CaP (relative difference to placebo, −36%; 95% confi dence interval, −48% to −21%; P < 0.001), but not RSRs CaOx and UA. In patients with UA stones, empagliflozin reduced RSR UA (−30%; 95% confidence interval, −44% to −12%; P = 0.002) but not RSRs CaOx and CaP. No serious or prespecified adverse events occurred. Thus, empagliflozin substantially reduced RSRs in nondiabetic adults with calcium and UA kidney stones. ClinicalTrials.gov registration: NCT04911660. © The Author(s) 2025.
Authors : Anderegg M.A.; Schietzel S.; Bargagli M.; Bally L.; Faller N.; Moor M.B.; Cereghetti G.M.; Roumet M.; Trelle S.; Fuster D.G.
Source : Nature Research
Article Information
| Year | 2025 |
| Type | Article |
| DOI | 10.1038/s41591-024-03330-x |
| ISSN | 10788956 |
| Volume |
You can download the article here
If You have any problem, contact us here